Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-06-25
1998-11-17
Krass, Frederick
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 17, 514 18, 530317, 530329, 530330, 435 712, 435118, 435120, 435863, 435864, 435865, 435866, 540524, 540526, A61K 3812
Patent
active
058376771
ABSTRACT:
The invention is directed toward the use of desferri-Exochelins to destroy cancer cells or retard or eliminate the growth of those cancer cells.
REFERENCES:
Blatt, Julie et al., "Failure to Alter the Course of Acute Myelogenous Leukemia in the Rat with Subcutaneous Deferoxamine," Leukemia Research vol. 15, No. 5, pp. 391-394, 1991.
Brodie, Chaya et al., "Neuroblastoma Sensitivity to Growth Inhibition by Deferrioxamine: Evidence for Block in G.sub.1 Phase of the Cell Cycle," Cancer Research 53, 3968-3975, Sep. 1, 1993.
Crowley, Stephen T. et al., "Platelet-Induced Vascular Smooth Muscle Cell Proliferation is Moderated . . . ," Circulation vol. 90, No. 4, 1908-1918, Oct. 1994.
Donfrancesco, Alberto et al., "Effects of a Single Course of Deferoxamine in Neuroblastoma Patients," Cancer Research 50, 4929-4930, Aug. 15, 1990.
Gobin, Jovana et al., "Exochelins of Mycobacterium Tuberculosis Remove Iron from Human Iron-Binding Proteins and Donate Iron to Mycobactins in the M. Tuberculosis Cell Wall," The Journal of Experimental Medicine vol. 183, No. 4, Apr. 1, 1996.
Gobin, Jovana et al., "Iron Acquisition by Mycobacterium Tuberculosis: Isolation and Characterization of a Family of Iron-Binding Exochelins," Proc. Natl. Aca. Sci. USA vol. 92, pp. 5189-5193, May 1995.
Lloyd, John B. et al., "Evidence that Desferrioxamine Cannot Enter Cells by Passive Diffusion," Biochemical Pharmacology, vol. 41, No. 9, pp. 136-1363, 1991.
Graham, Mark L. et al., "Simultaneous Measurement of Progesterone Receptors and DNA Indices by Flow Cytometry: Characterization of an Assay in Breast Cancer Cell Lines," Cancer Research, 49, 3934-3942, Jul. 15, 1989.
Reddel, Roger R. et al., Cell Cycle Effects of Iron Depletion on T-47D Human Breast Cancer Cells, Experimental Cell Research 161, 277-284, 1985.
Renton, Fiona J. and Thomas Jeitner, "Cell Cycle-Dependent Inhibition of the Proliferation of Human Neural Tumor Cell Lines by Iron Chelators," Biochemical Pharmacology, vol. 51, pp. 1553-1561, 1996.
Richardson, Des. and Prem Ponka, The Iron Metabolism of the Human Neuroblastoma Cell: Lack of Relationship Between the Efficacy of Iron Chelation and the Inhibition of DNA Synthesis, J Lab Clin Med, vol. 124, No. 5, 660-671, 1994.
Summers, M.R. et al., Studies in Desferrioxamine and Ferrioxamine Metabolism in Normal and Iron-Loaded Subjects, British Journal of Haematology, 42, 547-555, 1979.
Horwitz Kathryn B.
Horwitz Lawrence D.
Keystone BioMedical, Inc.
Krass Frederick
Ram Michael J.
LandOfFree
Method for the treatment of cancer with Exochelins of Mycobacter does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the treatment of cancer with Exochelins of Mycobacter, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the treatment of cancer with Exochelins of Mycobacter will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-884476